Brexanolone: First Global Approval

Brexanolone (ZULRESSO™) is an intravenously administered, small molecule, neuroactive steroid GABA A receptor positive allosteric modulator that was developed by Sage Therapeutics under license to the University of California for the treatment of postpartum depression (PPD). The formulation is a mix...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Drugs (New York, N.Y.) N.Y.), 2019-05, Vol.79 (7), p.779-783
1. Verfasser:	Scott, Lesley J.
Format:	Artikel
Sprache:	eng
Schlagworte:	AdisInsight Report Administration, Intravenous - methods Adolescent Adult Adults Allosteric properties Allosteric Regulation - drug effects Anesthesia beta-Cyclodextrins - administration & dosage beta-Cyclodextrins - adverse effects beta-Cyclodextrins - pharmacokinetics beta-Cyclodextrins - pharmacology beta-Cyclodextrins - therapeutic use Breastfeeding & lactation Cyclodextrins Depression, Postpartum - drug therapy Drug Approval Drug Combinations Drug dosages Drug therapy Drug Therapy, Combination - methods FDA approval Female Humans Internal Medicine Medicine Medicine & Public Health Mental depression Metabolites Middle Aged Pharmacology/Toxicology Pharmacotherapy Postpartum depression Pregnanolone Pregnanolone - administration & dosage Pregnanolone - adverse effects Pregnanolone - pharmacokinetics Pregnanolone - pharmacology Pregnanolone - therapeutic use Receptors, Steroid - metabolism Steroids Treatment Outcome United States United States Food and Drug Administration β-Cyclodextrin γ-Aminobutyric acid A receptors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!